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Abstract
Synergistic approach of magnesium and vitamin E may benefit clinical symptoms of patients with polycystic ovary syndrome
(PCOS) through improving their metabolic profiles and reducing oxidative stress and inflammation. This study was designed to
determine the effects of magnesium and vitamin E co-supplementation on hormonal status and biomarkers of inflammation and
oxidative stress in women with PCOS. This randomized, double-blind, placebo-controlled trial was conducted among 60 women
with PCOS, aged 18–40 years old. Participants were randomly divided into two groups to take 250 mg/day magnesium plus
400 mg/day vitamin E supplements or placebo (n = 30 each group) for 12 weeks. Fasting blood samples were taken at baseline
and after the 12-week intervention to quantify related variables. Magnesium and vitamin E co-supplementation resulted in a
significant reduction in hirsutism (β − 0.37; 95% CI, − 0.70, − 0.05; P = 0.02) and serum high-sensitivity C-reactive protein (hs-
CRP) (β − 0.67 mg/L; 95% CI, − 1.20, − 0.14; P = 0.01), and a significant increase in plasma nitric oxide (NO) (β 3.40 μmol/L;
95% CI, 1.46, 5.35; P = 0.001) and total antioxidant capacity (TAC) levels (β 66.32 mmol/L; 95% CI, 43.80, 88.84; P < 0.001).
Overall, magnesium and vitamin E co-supplementation for 12 weeks may benefit women with PCOS on hirsutism, serum hs-
CRP, plasma NO, and TAC levels. Clinical trial registration number http://www.irct.ir: IRCT2017082733941N8
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Introduction
Polycystic ovary syndrome (PCOS) is the most common met-
abolic disorder presented with hyperinsulinemic- and
hyperandrogenic-related disorders. This complex metabolic
disorder affects nearly 6% of women in reproductive age [1].
Earlier, investigators have documented a systemic low-grade
inflammation in women diagnosed with PCOS, which subse-
quently leads to long-term consequences of PCOS, including
enhanced risk of type 2 diabetes mellitus (T2DM) and cardio-
vascular disease (CVD) [2, 3]. On the other hand, oxidative
damage is closely linked with inflammation and further
clinical and metabolic disorders in women diagnosed with
PCOS [4].
The pathophysiology of PCOS might be associated with
the deficiency of essential micronutrients such as magnesium
and vitamin E in patients with insulin resistance and oxidative
stress. Current evidence has shown that women suffering from
PCOS have lower values of magnesium and vitamin E than
normal individuals [5, 6]. In addition, few studies conducted
in individuals with no PCOS have suggested that combined
magnesium and vitamin E intake might be useful to improve
metabolic profiles. A meta-analysis study conducted by
Simental-Mendia et al. [7] showed that magnesium intake
could reduce C-reactive protein (CRP) levels. Furthermore,
magnesium supplementation for 12 weeks resulted in a con-
siderable reduction of high-sensitivity C-reactive protein (hs-
CRP) and an elevation of total antioxidant capacity (TAC)
among diabetic patients with foot ulcer [8]. In another meta-
analysis, vitamin E supplementation decreased CRP levels
[9]. Recently, there is a growing interest to use the combina-
tion approach including combined magnesium and vitamin E,
which might improve metabolic profiles in a number of
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diseases with metabolic abnormalities. Due to the synergistic
impact of vitamin E and magnesium [10, 11], a further impor-
tant question will be whether combined vitamin and micronu-
trient would provide a better protection against disease. The
basis of this approach relies on a clinical correlation between
vitamin E and cellular magnesium as well as tissue glucose
metabolism [12].
Considering the antioxidant and anti-inflammatory effects
of magnesium with vitamin E, we hypothesized that magne-
sium plus vitamin E might be useful on metabolic profiles in
women with PCOS. However, data on studies investigating
the impact of magnesium plus vitamin E on hormonal profiles,
and biomarkers of inflammation and oxidative stress among
women with PCOS, are scarce. Therefore, this study evaluates
the effects of magnesium with vitamin E co-supplementation
on metabolic profiles in women with PCOS.
Methods
Trial Design and Participants
This randomized, double-blinded, placebo-controlled clinical
trial is registered in the Iranian clinical trials website (http://
www.irct.ir: IRCT2017082733941N8), has followed the
Declaration of Helsinki guideline, and informed consent was
given by all participants. The study protocol was approved by
the Ethics Committee of Arak University of Medical Sciences
(AUMS). This study was conducted among 60 women with
PCOS, diagnosed based on the Rotterdam Criteria [13], aged
18–40 years, who referred to the Kosar Clinic in Arak, Iran,
between October 2017 and January 2018. The main exclusion
criteria were as follows: pregnancy, adrenal hyperplasia,
androgen-secreting tumors, hyperprolactinemia, thyroid dys-
function, diabetes and other metabolic disorders at enrollment,
and antioxidant and/or anti-inflammatory supplements within
3 months prior to the enrollment in the study.
Study Design
All patients were matched for BMI and age. They were then
randomly allocated into two groups to receive either 250 mg/
day magnesium oxide (Twenty First Century Pharmaceutical
Company, AZ, USA) plus 400 IU/day vitamin E (Zahravi
Pharmaceutical Company, Tabriz, Iran) (n = 30) or placebo
(Barij Essence Pharmaceuticals, Kashan, Iran) (n = 30) for
12 weeks. The placebos were matched in color, shape, size,
packaging, smell, and taste with the vitamin E andmagnesium
capsules. The compliance rate was assessed by measuring
serum magnesium levels. Intake of the magnesium, vitamin
E, and placebo capsules was monitored through asking partic-
ipants to return the medication containers. To increase the
compliance rate, all patients received brief daily cell phone
reminders to take the supplements. Patients were requested
to have their regular physical activity and not to take any extra
nutritional supplements during the 12-week trial. All patients
completed a 3-day food record and three physical activity
records at the baseline of the study, weeks 3, 6, and 9, and
the end of the intervention. Daily macro- and micronutrient
intakes were calculated by analyzing food records using the
Nutritionist IV software (First Databank, San Bruno, CA).
Anthropometric Measures
Patient’s weight and height were measured after an overnight
fasting, using a standard scale (Seca, Hamburg, Germany), at
both the onset of the study and after the 12-week intervention.
BMI was calculated as weight in kilogram divided by height
in meters squared.
Clinical Assessments
Hirsutism was determined using a modified Ferriman–
Gallwey scoring system, as the clinical outcome [14].
Biochemical Assessment
Fasting blood samples were collected at the beginning and end
of the trial, at the Arak reference laboratory. Serum total tes-
tosterone and sex hormone-binding globulin (SHBG) were
measured using Elisa kits (DiaMetra, Milano, Italy) with
inter- and intra-assay coefficient of variations (CVs) less than
7%. Serum hs-CRP concentrations were measured using an
ELISA kit (LDN, Nordhorn, Germany) with the intra- and
inter-assay CVs less than 7%. Other biomarkers were assessed
as follows: plasma nitric oxide (NO) using the Griess method
[15], TAC using ferric reduction antioxidant power method
developed by Benzie and Strain [16], glutathione (GSH) ap-
plying Beutler et al.’s method [17], and malondialdehyde
(MDA) concentrations using the thiobarbituric acid reactive
substance method [18] with the inter- and intra-assay CVs less
than 5%.
Sample Size
Sample size was calculated using the standard formula for
clinical trials, considering type one error (α) of 0.05 and type
two error (β) of 0.20 (power = 80%). According to a previ-
ously published study [19], we used 1.93 mg/L as the effect
size (d) of hs-CRP and 2.4 mg/L as standard deviation (SD).
Using this information, 25 individuals were required to be
included in each treatment group. Considering 5 probable
dropouts in each group, the final sample size was determined
as 30 patients in each group.
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Randomization
Randomization was conducted using computer-generated ran-
dom numbers. Randomization and allocation were concealed
from the researchers and patients until the final analyses were
completed. The randomized allocation sequence, enrolling pa-
tients, and allocating them into intervention groups were per-
formed by a trained staff at the clinic.
Statistical Methods
Anthropometric measures and dietary intakes were compared
between intervention groups, using independent samples t
test. Multiple linear regression models were used to assess
treatment effects on the study outcomes after adjusting for
confounding variables including the baseline values, age,
and BMI. The effect sizes were presented as the mean differ-
ences with 95% confidence intervals. Paired-samples t test
was used to detect within-group differences. The normality
of model residual was tested using the Kolmogorov-
Smirnov test. The P value of < 0.05 was considered as statis-
tically significant. All statistical analyses were conducted
using the Statistical Package for Social Science version 18
(SPSS Inc., Chicago, IL, USA).
Results
In the current study, all 60 subjects (intervention (n = 30) and
placebo (n = 30)) completed the trial (Fig. 1). Overall, the
compliance rate in this study was high, such that more than
90% of the capsules were consumed throughout the study in
both groups. No side effects were reported following co-
administration of magnesium and vitamin E capsules in pa-
tients with PCOS throughout the study.
Mean age, height, weight, and BMI at baseline and end-of-
trial were not statistically different between intervention
groups (Table 1).
Mean dietary macro- and micronutrient intakes were also
not statistically different between the two groups throughout
the trial (data not shown).
After the 12-week intervention, magnesium and vitamin E
co-supplementation significantly reduced hirsutism (β − 0.37;
95% CI, − 0.70, − 0.05; P = 0.02) and serum hs-CRP (β −
0.67 mg/L; 95% CI, − 1.20, − 0.14; P = 0.01), and significant-
ly increased serum magnesium (β 0.17 mg/dL; 95% CI, 0.12,
0.21; P < 0.001), plasma NO (β 3.40 μmol/L; 95% CI, 1.46,
5.35; P = 0.001), and TAC levels (β 66.32 mmol/L; 95% CI,
43.80, 88.84; P < 0.001) compared with the placebo (Table 2).
Serum total testosterone, SHBG, plasma GSH, and MDA
levels did not significantly change with magnesium and vita-
min E co-supplementation. Within-group changes demon-
strated a significant reduction in hirsutism (P = 0.02), and a
significant increase in serum magnesium (P < 0.001), SHBG
(P = 0.004), plasma NO (P < 0.001), TAC (P < 0.001), and
GSH (P = 0.03) in the magnesium and vitamin E group. In
addition, within-group change showed a significant increase
in serum hs-CRP (P = 0.03) in the placebo group.
Discussion
We evaluated the effect of co-administration of magnesium
and vitamin E, to our best knowledge for the first time, on
metabolic status in patients with PCOS. The results showed
that taking magnesium and vitamin E supplements together
for 12 weeks had beneficial effects on hirsutism, hs-CRP, NO,
and TAC levels.
Effects on Hormonal Profiles
Women with PCOS are susceptible to multiple metabolic dis-
orders [20, 21]. The current study demonstrated that magne-
sium and vitamin E co-supplementation for 12 weeks was
associated with a significant reduction in hirsutism, but did
not affect serum total testosterone and SHBG levels. Our pre-
vious study demonstrated that magnesium-zinc-calcium-
vitamin D co-supplementation after 12 weeks to women with
PCOS significantly decreased hirsutism, but did not affect
other hormonal profiles [22]. In addition, vitamin E (400 IU/
day) and omega-3 (1000 mg/day) co-supplementation for
12 weeks to women with PCOS significantly improved total
and free testosterone levels, but did not affect other endocrine
parameters [23]. In another study, coenzyme Q10 (200 mg/
day) with or without vitamin E (400 IU/day) supplementation
for 8 weeks to women with PCOS had beneficial effects on
serum total testosterone levels, but did not influence SHBG
concentrations [24]. A cross-sectional study demonstrated an
inverse association between serum α-tocopherol and circulat-
ing testosterone, estradiol, and SHBG levels in smoker men
[25]. Elevated androgen level which is a hallmark of PCOS in
a self-perpetuating cycle promotes hyperandrogenism and re-
sults in neuroendocrine abnormality [26]. Previous evidence
showed that reducing androgens is attributed to the restoration
of ovulatory functions, decreasing hirsutism, and improving
health-related quality of life [27, 28]. The absence of benefi-
cial effects of magnesium and vitamin E co-supplementation
on total testosterone and SHBGmay be due to low-dose mag-
nesium and vitamin E used as well as short-duration interven-
tion. A number of potential mechanisms through which mag-
nesium and vitamin E may improve ovarian functions are
proposed including the antioxidant and anti-inflammatory ac-
tivities of magnesium and vitamin E, as well as their effects on
improved insulin sensitivity [24, 29, 30].
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Effects on Biomarkers of Inflammation and Oxidative
Stress
The co-supplementation of magnesium and vitamin E for
12 weeks was found to significantly decrease serum hs-CRP
and increase plasma NO and TAC levels in patients with
PCOS, but did not affect plasma GSH and MDA levels. We
have previously showed that taking magnesium plus zinc sup-
plements for 12 weeks by women with PCOS had beneficial
effects on hs-CRP and TAC levels [19]. In addition, a meta-
analysis conducted by Simental-Mendia et al. [7] showed that
magnesium supplementation could decrease CRP levels in
people with high inflammation (CRP levels > 3 mg/dL). A
4-week magnesium supplementation to rugby players and
people with sedentary lifestyle significantly decreased oxida-
tive damage [31]. However, magnesium supplementation at a
dosage of 250 mg/day as magnesium oxide after 8 weeks to
middle-aged overweight women did not influence inflamma-
tory markers [32]. Moreover, the administration of 440 mg
magnesium supplements as magnesium oxide 3 times per
week for 6 months to hemodialysis patients did not influence
CRP concentrations [33]. Anti-inflammatory and antioxida-
tive effects of vitamin E have been previously reported. In a
meta-analysis conducted by Saboori et al. [9], vitamin E sup-
plementation significantly reduced CRP levels. Furthermore,
Fig. 1 Summary of patient flow diagram
Table 1 General characteristics of study participants
Placebo group
(n = 30)
Magnesium
plus vitamin
E group (n = 30)
P1
Age (years) 26.0 ± 3.7 27.2 ± 7.1 0.42
Height (cm) 159.5 ± 4.9 159.9 ± 4.8 0.71
Weight at study baseline (kg) 70.9 ± 10.3 69.4 ± 10.7 0.58
Weight at end-of-trial (kg) 70.7 ± 10.4 69.2 ± 10.6 0.57
Weight change (kg) − 0.1 ± 0.6 − 0.2 ± 0.3 0.62
BMI at study baseline (kg/m2) 27.9 ± 4.2 27.1 ± 4.2 0.48
BMI at end-of-trial (kg/m2) 27.8 ± 4.2 27.0 ± 4.1 0.47
BMI change (kg/m2) − 0.1 ± 0.2 − 0.1 ± 0.1 0.63
Data are means ± SDs
1Obtained from independent-samples t test
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vitamin E supplementation at a dosage of 200 mg/day for
12 weeks to workers significantly reduced biomarkers of
oxidative stress [34]. However, no significant changes in
biomarkers of oxidative damage were observed following
the administration of 400 IU/day vitamin E for 8 weeks to
patients with chronic obstructive pulmonary disease [35].
Synergistic anti-inflammatory effects of vitamin E plus
magnesium might boost their impact on clinical and bio-
chemical symptoms. It is now obvious that PCOS is a pro-
inflammatory condition linking with oxidative stress [36].
Impaired antioxidative defense and increased inflammato-
ry markers such as CRP contribute to insulin resistance and
the promotion of atherosclerosis which increase the risk of
CVD [37]. Anti-inflammatory effects of magnesium sup-
plements may be due to its antagonism to calcium [38] and
blocking nuclear factor-kappa B (NF-κB) [39]. In addition,
anti-inflammatory and antioxidative effects of vitamin E
may be explained by suppressing NF-κB and JAK-signal
transducer and activator of transcription 6 (STAT6) or
JAK-STAT3 signaling pathways in various types of cells
[40].
This study had a few limitations. In the present study, we
did not evaluate circulating vitamin E before and after supple-
mentation. Further, this study did not assess gene expression
related to inflammatory cytokines and biomarkers of oxidative
stress.
Conclusions
In summary, the current study demonstrated that taking mag-
nesium and vitamin E supplements together for 12 weeks by
patients with PCOS has beneficial effects on hirsutism, hs-
CRP, NO, and TAC, but did not affect serum total testoster-
one, SHBG, plasma GSH, and MDA levels.
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Table 2 Hormonal status and biomarkers of inflammation and oxidative stress at baseline and after the 12-week intervention in subjects with polycystic
ovary syndrome
Variables Placebo group (n = 30) Magnesium plus vitamin E
group (n = 30)
Difference in outcome measures
between magnesium plus vitamin
E and placebo treatment groups1
Baseline Week 12 P2 Baseline Week 12 P2 β (95% CI) P3
Magnesium (mg/dL) 1.89 ± 0.12 1.88 ± 0.11 0.59 1.94 ± 0.20 2.10 ± 0.15 < 0.001 0.17 (0.12,0.21) < 0.001
Total testosterone (ng/mL) 1.2 ± 0.5 1.2 ± 0.6 0.80 1.4 ± 0.8 1.3 ± 0.7 0.26 0.02 (− 0.09, 0.14) 0.63
SHBG (nmol/L) 48.5 ± 15.1 49.2 ± 15.2 0.57 51.4 ± 26.4 62.9 ± 36.3 0.004 − 0.03 (− 0.13,0.07) 0.56
FAI 0.09 ± 0.05 0.09 ± 0.05 0.46 0.15 ± 0.16 0.11 ± 0.11 0.08 0.12 (− 0.01, 0.27) 0.08
mF-G scores 13.8 ± 3.8 13.8 ± 3.8 0.57 14.9 ± 2.9 14.6 ± 2.5 0.02 − 0.37 (− 0.70, − 0.05) 0.02
hs-CRP (mg/L) 3.5 ± 1.5 3.7 ± 1.5 0.03 3.7 ± 1.9 3.1 ± 1.7 0.05 − 0.67 (− 1.20, − 0.14) 0.01
NO (μmol/L) 36.6 ± 5.6 37.0 ± 5.8 0.34 34.4 ± 2.3 38.7 ± 4.0 < 0.001 3.40 (1.46, 5.35) 0.001
TAC (mmol/L) 513.7 ± 81.7 514.5 ± 77.3 0.90 522.4 ± 30.6 590.7 ± 52.2 < 0.001 66.32 (43.80, 88.84) < 0.001
GSH (μmol/L) 481.1 ± 101.2 483.8 ± 94.2 0.50 508.1 ± 69.1 519.4 ± 47.7 0.03 12.14 (− 0.17, 24.46) 0.05
MDA (μmol/L) 2.4 ± 0.5 2.5 ± 0.5 0.15 2.7 ± 0.2 2.6 ± 0.2 0.11 − 0.10 (− 0.28, 0.08) 0.27
Data are mean ± SDs
1 BOutcome measures^ refers to the change in values of measures of interest between baseline and week 12. β (difference in the mean outcome measures
between treatment groups (magnesium plus vitamin E group = 1 and placebo group = 0))
2 Obtained from paired-samples t test
3 Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age, and baseline BMI)
FAI, free androgen index; GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; mF-G, modified Ferriman–Gallwey; MDA,
malondialdehyde; NO, nitric oxide; SHBG, sex hormone-binding globulin; TAC, total antioxidant capacity
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